Diane Prager

Medicine · Health Sciences

30h-index6.7kcitations69works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(19), Growth Hormone and Insulin-like Growth Factors(16), T-cell and Retrovirus Studies(15), Vector-Borne Animal Diseases(12), Animal Disease Management and Epidemiology(11)

Publications69 total

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
2017· 97 cited
SmartCare at a community cancer center.
Journal of Clinical Oncology·2015
Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Trial of Nab-Paclitaxel (Nab-P) Plus Gemcitabine (Gem) Vs Gem Alone for Patients with Metastatic Pancreatic Cancer (Mpc)
Annals of Oncology·2014Open Access
Nab-Paclitaxel Plus Gemcitabine Vs Gemcitabine Alone for Patients with Metastatic Pancreatic Cancer: Influence of Primary Pancreatic Tumor Location on Efficacy and Treatment Exposure in the Mpact Phase III Trial
Annals of Oncology·2014· 1 citedOpen Access
A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology·2013· 21 citedOpen Access
Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2007· 292 cited
Randomized Phase II Trial of Pemetrexed Combined With Either Cisplatin or Carboplatin in Untreated Extensive-Stage Small-Cell Lung Cancer
Journal of Clinical Oncology·2006· 81 cited
A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results
Journal of Clinical Oncology·2006· 73 cited
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2005· 1.5k citedOpen Access
P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study
Lung Cancer·2005· 14 cited
O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial
Lung Cancer·2005· 25 cited
P-796 A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC)
Lung Cancer·2005
PD-143 Analysis of EGFr gene mutations in non-small cell lungcarcinoma (NSCLC) patients (pts) treated with panitumumab plus paclitaxel and carboplatin or chemotherapy alone
Lung Cancer·2005
Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1<sup>st</sup>-line treatment in patients with NSCLC
Journal of Clinical Oncology·2005· 43 cited
A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC
Journal of Clinical Oncology·2005· 41 cited
A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC)
Journal of Clinical Oncology·2005· 6 cited
Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-Small-Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial
Journal of Clinical Oncology·2005· 119 cited
156 A phase I dose-escalation study with oral LY317615 (L) in combination with capecitabine (C) in advanced cancer patients
European Journal of Cancer Supplements·2004
Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer
Journal of Clinical Oncology·2004· 4 cited
Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE
Journal of Clinical Oncology·2004· 49 cited
page 1 of 4Next →

Frequent Co-authors

Шломо Мелмед(12), Roy S. Herbst(11), Naoki Mori(9), Hironori Yamasaki(7), Mark G. Kris(6), Róbert Hermann(5), Bruce E. Johnson(5), John V. Heymach(5), Chandra P. Belani(4), Alan Sandler(4), David Cella(4), Edit Csada(4), Jaromı́r Roubec(4), P C Hoffman(4), Alan B. Sandler(4), S Gebremedhin(4), Isaiah W. Dimery(4), Ronald B. Natale(3), Joan H. Schiller(3), H. Spiridonidis(3)